Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTML2WA)

• DTT Name: Tubulin (TUB) DTT Info
• Gene Name: TUB

Molecule-Related Drug & Molecule List

6 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[1]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[2]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[3]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[1]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[1]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[4]

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[5]
BMS-184476	DMDPLEM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BMS-275183	DMQL3VS	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
CRYPTOPHYCIN 52	DM16IMT	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[11]
Milataxel	DM50Z4U	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
Soblidotin	DMO4EYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
BAL-101553	DMPFGL8	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[14]
E 7974	DM3LOF1	Ovarian cancer	2C73	Phase 1	[5]
SDZ-LAV-694	DM8SINB	Actinic keratosis	EK90.0	Phase 1	[15]

11 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epothilone B	DMM5ZX6	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[16]
Larotaxel	DMCM239	Bladder cancer	2C94	Discontinued in Phase 3	[17]
ATX-201	DMWJ245	Actinic keratosis	EK90.0	Discontinued in Phase 2	[18]
Cryptophycin	DM73C4K	N. A.	N. A.	Discontinued in Phase 2	[19]
ERBULOZOLE	DM03I7V	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[20]
RHIZOXIN	DMQ4IKZ	Breast cancer	2C60-2C65	Discontinued in Phase 2	[21]
ABJ-879	DMJTIUP	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[22]
Discodermolide	DMAR068	Immune System disease	4A01-4B41	Discontinued in Phase 1	[23]
FCE-28161	DMSFA7L	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[24]
TALTOBULIN	DM1ZYCA	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[25]
21-AMINOEPOTHILONE B	DMTH52F	Solid tumour/cancer	2A00-2F9Z	Terminated	[27]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABI-013	DMQ0NU1	Solid tumour/cancer	2A00-2F9Z	Preclinical	[26]

30 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one	DMK6CD9	Discovery agent	N.A.	Investigative	[28]
2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde	DMTEQU8	Discovery agent	N.A.	Investigative	[29]
2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one	DMD8ZUH	Discovery agent	N.A.	Investigative	[30]
2-m-Tolyl-1H-[1,8]naphthyridin-4-one	DM9ZVHJ	Discovery agent	N.A.	Investigative	[28]
2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol	DMCGID6	Discovery agent	N.A.	Investigative	[31]
2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol	DM6CAYV	Discovery agent	N.A.	Investigative	[32]
2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol	DM9LY0Z	Discovery agent	N.A.	Investigative	[33]
2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one	DMTSF6A	Discovery agent	N.A.	Investigative	[28]
2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one	DM12YH4	Discovery agent	N.A.	Investigative	[28]
5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	DMU618S	Discovery agent	N.A.	Investigative	[28]
5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	DMH1IVN	Discovery agent	N.A.	Investigative	[28]
6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	DMAQGZR	Discovery agent	N.A.	Investigative	[28]
7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one	DM7LGDC	Discovery agent	N.A.	Investigative	[28]
AL-209	DM7XHDC	Central nervous system disease	8A04-8D87	Investigative	[34]
AL-309	DM69X2Z	Central nervous system disease	8A04-8D87	Investigative	[34]
CENTAUREIDIN	DMCLXO0	Discovery agent	N.A.	Investigative	[35]
COLCHINOL	DM326VN	Discovery agent	N.A.	Investigative	[36]
COMBETASTATIN	DMIKD8X	Discovery agent	N.A.	Investigative	[37]
Eleutherobin	DMMVZU0	Discovery agent	N.A.	Investigative	[38]
GNF-PF-117	DM3INUK	Discovery agent	N.A.	Investigative	[39]
Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate	DMS8MBI	Discovery agent	N.A.	Investigative	[40]
MR-22388	DMIQ8GL	Discovery agent	N.A.	Investigative	[41]
MYOSEVERIN	DMX1POR	Discovery agent	N.A.	Investigative	[42]
NSC-106970	DMHK0F6	Discovery agent	N.A.	Investigative	[35]
NSC-664171	DMEF603	Discovery agent	N.A.	Investigative	[43]
NSC-679036	DMPO2RU	Discovery agent	N.A.	Investigative	[28]
PHENSTATIN	DMJ5GY7	Discovery agent	N.A.	Investigative	[44]
Sarcodictyin A	DMZR4FX	Discovery agent	N.A.	Investigative	[45]
Thiocolchicine	DMJSKIP	Discovery agent	N.A.	Investigative	[46]
WR85915	DM9V0KP	Discovery agent	N.A.	Investigative	[47]

References

• [1] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [2] Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
• [3] Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
• [4] Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
• [5] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [6] Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218.
• [7] Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
• [8] A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31.
• [9] Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9.
• [10] Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
• [11] 2011 Pipeline of ZioPharm.
• [12] J Clin Oncol 28, 2010 (suppl; abstr e13075).
• [13] Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers. Recent Patents on Anti-Infective Drug Discovery 12/2009; 4(3):164-82.
• [16] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [17] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [18] Clinical pipeline report, company report or official report of Kythera Biopharmaceuticals.
• [19] Single-walled tubulin ring polymers. Biopolymers. 2007 Aug 5-15;86(5-6):424-36.
• [20] Influence of the synthetic microtubule inhibitor erbulozole (P.I.N.N.) (R 55 104), a new tubulozole congener, and gamma irradiation on murine tumors in vivo. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1499-504.
• [21] Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51.
• [22] Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007 Jul;18 Suppl 5:v9-15.
• [23] The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, andinhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 1997 Oct;52(4):613-22.
• [24] CN patent application no. 101065129, A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer.
• [25] Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1535-8.
• [26] Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Research. 01/2011; 70(8 Supplement):2617-2617.
• [27] Tubulin-Interactive Natural Products as Anticancer Agents. Correction in: J Nat Prod. 2011 May 27; 74(5): 1352.
• [28] Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56.
• [29] Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72.
• [30] Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7.
• [31] Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67.
• [32] Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4.
• [33] The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12.
• [34] Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12.
• [35] Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8.
• [36] Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9.
• [37] Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000.
• [38] Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res. 1998 Mar 15;58(6):1111-5.
• [39] Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56.
• [40] New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54.
• [41] Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64.
• [42] Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500.
• [43] Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62.
• [44] Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42.
• [45] The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry. 1999 Apr 27;38(17):5490-8.
• [46] Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51.
• [47] Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol Biochem Parasitol. 2000 Oct;110(2):223-36.